Global
Contact Us
DKSH has signed an agreement to acquire the Meliane oral contraceptive brand from Bayer across 30 markets in Europe, North Africa, Asia, and the Middle East. The acquisition is in line with DKSH’s strategy to expand its Healthcare Own Brands portfolio and strengthen its presence in higher-value segments and services.
Corrigendum to the ad hoc announcement of 17 July 2026: EPS in H1 2026 was CHF 1.56 (not CHF 1.67), representing growth of 10.6% compared to H1 2025 (not 18.2%). The full text of the corrected announcement is as follows: Net sales of CHF 5.5 billion (+4.9% at CER1) Core EBIT of CHF 163.4 million (+3.6% at CER) Core EBIT margin of 3.0% Increase of Earnings per share (EPS) by 10.6% to CHF 1.56 Free Cash Flow of CHF 147.7 million (130.8% cash conversion rate) Three acquisitions announced in H1 2026 and good pipeline for H2 Stronger H2 expected: improving commercial momentum, data center project pipeline and M&A potential Mid-term roadmap confirmed
Net sales of CHF 5.5 billion (+4.9% at CER1) Core EBIT of CHF 163.4 million (+3.6% at CER) Core EBIT margin of 3.0% Increase of Earnings per share (EPS) by 18.2% to CHF 1.67 Free Cash Flow of CHF 147.7 million (130.8% cash conversion rate) Three acquisitions announced in H1 2026 and good pipeline for H2 Stronger H2 expected: improving commercial momentum, data center project pipeline and M&A potential Mid-term roadmap confirmed
DKSH Hong Kong and Hua Medicine expand their strategic partnership, building on the successful delivery of the first Regulatory Affairs service in Macau, combining their respective strengths in innovative drug development and market expansion to accelerate the go-to-market and market introduction of pharmaceutical products for diabetes treatment in Hong Kong. This collaboration aims to enhance patient access to innovative diabetes therapies while creating long-term value for regional healthcare systems.
DKSH has achieved another industry-leading milestone by receiving the AA MSCI ESG Rating. This improved rating, advancing from “A” to “AA,” positions DKSH in the prestigious “Leader” category. The recognition highlights DKSH’s strong performance in responsible business practices and its ongoing commitment to sustainable growth.
DKSH China has been recognized for the third consecutive year as one of the Best Workplaces for Women™ in Greater China, reaffirming its strong commitment to fostering an inclusive, eq-uitable, and people-centric workplace where women are empowered to grow and succeed.
DKSH has closed an agreement to acquire the business of Kinematic Resources Sdn. Bhd. (“Kinematic”), a leading Malaysian distributor of high-value scientific and analytical instruments in Malaysia. With this transaction, DKSH Technology further scales its operations in Malaysia in line with the Business Unit’s strategy to solidify its position as a leading scientific solutions provider in Asia and Beyond.
DKSH China’s Business Unit Performance Materials has been awarded the “PCHi 2026 Fountain Award (Moisturizing – Silver)” for its innovative active ingredient SACRANEXSacranex™ from Sun Chemical. This award recognizes the breakthrough moisturizing performance of the ingredient and reinforces DKSH’s commitment to bringing high-quality, natural-based solutions to the personal care market.
At the Extraordinary General Meeting (“EGM”) that was held today in Kuala Lumpur, Malaysia, the minority shareholders of DKSH Holdings (Malaysia) Berhad (“DHMB”) have rejected the take-over offer that DKSH Holding Ltd. (“DKSH”) submitted through its subsidiaries.
Reach out to our Group Media Relations team for any inquiries.
Manager, Group Media Relations
Contact us to discover new opportunities.